Conceptualizing overdiagnosis in cancer screening

Journal of the National Cancer Institute

Volumn 107, Issue 4, 2015, Pages

  Marcus, Pamela M ^c   Prorok, Philip C ^a   Miller, Anthony B ^b   Devoto, Emily J ^c   Kramer, Barnett S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CHILDHOOD CANCER; HUMAN; LIFESPAN; LUNG CANCER; NEUROBLASTOMA; PATIENT CODING; PRIORITY JOURNAL; PROSTATE CANCER; SCIENTIST; ADVERSE EFFECTS; ASYMPTOMATIC DISEASES; BLOOD; CAUSE OF DEATH; CONCEPT FORMATION; EARLY CANCER DIAGNOSIS; INFANT; LIFE EXPECTANCY; LUNG NEOPLASMS; MALE; MASS SCREENING; MORTALITY; NEOPLASMS; PROSTATIC NEOPLASMS; REMISSION; TIME FACTOR; UNNECESSARY PROCEDURE; WATCHFUL WAITING;

PROSTATE SPECIFIC ANTIGEN;

ASYMPTOMATIC DISEASES; CAUSE OF DEATH; CONCEPT FORMATION; EARLY DETECTION OF CANCER; HUMANS; INFANT; LIFE EXPECTANCY; LUNG NEOPLASMS; MALE; MASS SCREENING; NEOPLASMS; NEUROBLASTOMA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REMISSION, SPONTANEOUS; TIME FACTORS; UNNECESSARY PROCEDURES; WATCHFUL WAITING;

EID: 84930717504     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv014     Document Type: Article

References (18)

1. Morrison AS. Screening in chronic disease. 2nd ed. New York, NY: Oxford University Press;1992.
2. Miller AB. Conundrums in screening for cancer. Int J Cancer. 2010;126(5):1039-1046.
3. Levy IG, Dougherty GE, Hill GB, Woods WG, Bernstein ML. Neuroblastoma. In: KramerBS, GohaganJK, ProrokPC, eds. Cancer screening: theory and practice. New York, NY: Marcel Dekker;1999:409-429.
4. Tsubono Y, Hisamichi S. A halt to neuroblastomas screening in Japan. New Engl J Med. 2004;350(19):2010-2011.
5. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. New Engl J Med. 2002;346(14):1047-1053.
6. Woods WF, Gao R-N, Shuster JJ, et al. Screening of infants and mortality due to neuroblastomas. New Engl J Med. 2002;346(14):1041-1046.
7. Tanaka M, Kigasawa H, Kato K, et al. A prospective study of a long-term followup of an observational program for neuroblastomas detected by mass screen. Pediatr Blood Cancer. 2010;54(4):573-578.
8. Hero B, Simon T, Spitz R, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NM95-S and NB97. J Clin Oncol. 2008;26(9):1504-1510.
9. Fritsch P, Kerbl R, Lackner H, Urban C. "Wait and see"strategy in localized neuroblastoma in infants: an option not only for cases detected by mass screening. Pediatr Blood Cancer. 2004;43(6):679-682.
10. Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst. 2013;105(14):1050-1058.
11. Yin M, Bastacky S, Chandran U, Becich MJ, Dhir R. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol. 2008;179(3):892-895.
12. Konety BR, Bird VY, Deorah S, Dahmoush L. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol. 2005;174(5):1785-1788.
13. Soos G, Tsakiris I, Szanto J, Turzo C, Haas PG, Dezso B. The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur Urol. 2005;48(5):739-744.
14. Schroder FH. Prostate cancer. In: KramerBS, GohaganJK, ProrokPC, eds. Cancer screening: theory and practice. New York, NY: Marcel Dekker;1999:461-514.
15. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203-213.
16. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932-942.
17. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.
18. US National Cancer Institute. Cancer Data Access System. Available at https://biometry.nci.nih.gov/cdas/. Accessed on August 19, 2014.https://biometry.nci.nih.gov/cdas/. Accessed on August 19, 2014.